Effects of B7-H3 expression on tumour-infiltrating immune cells and clinicopathological characteristics in non–small-cell lung cancer
- 1 July 2020
- journal article
- research article
- Published by Elsevier in European Journal of Cancer
- Vol. 133, 74-85
Abstract
No abstract availableKeywords
Funding Information
- College of Medicine, Seoul National University (800-20190002)
- Seoul National University Hospital (0320190380)
- Seoul National University Hospital (2019-1757)
This publication has 36 references indexed in Scilit:
- PD-1/PD-L1 Blockade Therapy in Advanced Non-Small-Cell Lung Cancer: Current Status and Future DirectionsThe Oncologist, 2019
- Predictive biomarkers of response for immune checkpoint inhibitors in non–small-cell lung cancerEuropean Journal of Cancer, 2019
- B7H3 As a Promoter of Metastasis and Promising Therapeutic TargetFrontiers in Oncology, 2018
- Precision Diagnosis and Treatment for Advanced Non–Small-Cell Lung CancerNew England Journal of Medicine, 2017
- New checkpoints in cancer immunotherapyImmunological Reviews, 2017
- Molecular Pathways: Targeting B7-H3 (CD276) for Human Cancer ImmunotherapyClinical Cancer Research, 2016
- The contrasting role of B7-H3Proceedings of the National Academy of Sciences, 2008
- Triggering receptor expressed on myeloid cell-like transcript 2 (TLT-2) is a counter-receptor for B7-H3 and enhances T cell responsesProceedings of the National Academy of Sciences, 2008
- The B7 family member B7-H3 preferentially down-regulates T helper type 1–mediated immune responsesNature Immunology, 2003
- B7-H3: A costimulatory molecule for T cell activation and IFN-γ productionNature Immunology, 2001